ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
Clinical follow-up of patients with HBeAg positive chronic hepatitis B infection: A long-term observational study
1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
2Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kartal Dr. Lutfi Kırdar Education and Research Hospital, Istanbul, Turkey
3Department of Internal Medicine, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
Hepatology Forum 2022; 2(3): 57-60 DOI: 10.14744/hf.2021.2021.0011 PMCID: PMC9243757
Full Text PDF


Background and Aim: We aimed to analyze the demographic, laboratory, and clinical characteristics of patients with HBeAg positive chronic hepatitis B infection in tertiary care centers in Istanbul.
Material and Methods: We conducted an observational cohort with ≥18-year-old patients with HBeAg positive chronic hepatitis B infection, who were followed up in three tertiary care centers in Istanbul between January 2000 and August 2018, were evaluated by reviewing electronic and recorded files. The Ethical Committee of Istanbul Medipol University approved this study (Protocol no: 10840098-604.01.01-E.44136). During the polyclinic interview, consent was obtained from patients for analysis and publication.
Results: The mean age of the 64 patients was 30 (range 18-39) years, and 50% (32) of them were males. The mean follow-up period of the patients was 67 (18-180) months. Twenty-four patients were treated with at least one antiviral in their follow-up, and only 2 (3.1%) of these patients developed HBeAg seroconversion without antiviral treatment. HBeAg (+) chronic hepatitis B developed in 4 of the patients after the immune-active period. None of the patients and first-degree relatives had hepatocellular carcinoma (HCC).
Conclusion: The rationality of antiviral treatment and HCC development risk in these patients still remains elusive.